The rest of this story is for members
The rest is for members
The story continues: the full timeline, the transaction ranges, and the names the forms carry.
Premium comes through the Telegram channel. Already have a code? Sign in to activate it.
Premium
AVBP
The market fled ArriVent twice, and Guggenheim did the opposite
Despite sharp declines following clinical trial results, Guggenheim raises ArriVent Biopharma's price target to $30 and explains why the market is wrong.
Other Stories
Meta spent more money in the quarter than its business brought in, and the stock plunged 7%. But look what 23 investment firms did that same day
AnalystsMETA1d ago3 min read
The quiet transformation: former bitcoin miner hosts AI chips for microsoft
On Our RadarIOND1d ago2 min read
Insider purchase at Liberty Energy: director buys below the IPO price
PremiumInsidersLBRT3h ago2 min read